Novel antiplatelet agents, development

The development of novel and powerful antiplatelet agents has improved outcomes after PCI. In the CADILLAC trial, the use of a glycoprotein Ilb-IIIa inhibitor improved outcome in those treated with either balloon angioplasty or an intracoronary stent (21). Similarly, treatment with clopidogrel, a thienopyridine, decreases the incidence of adverse events after PCI (22,23). Neither thienopyridines nor glycoprotein Ilb-IIIa antagonists were available at the time the early trials designed to test the potential clinical efficacy of a combined approach were performed. 

CONTENTS Preface. Bruce E. Maryanoff and Cynthia A. Maryanoft. Novel An-tipsychotics with Unique D /5-HT1A Affinity and Minimal Extrapyramidal Side Effect Liability. Allen B. Reitz and Malcolm K. Scott. Antiplatelet and Antithrombotic Agents From Viper Venom Proteins, to Peptides and Peptidomimetics. to Small Organic Molecules, Peter L. Barker and Robert R. Webb. II. Discovery and Preclinical Development of the Serotonin Reuptake Inhibitor Sertraline, Willard M. Welch. Boronic Acid Inhibitors of Dipeptidyipeptidase IV A New Class of Immunosuppressive Agents, Roger J. Snow. Index. 

---